Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Stoke Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Ed Kaye
İcra Kurulu Başkanı
US$3.5m
Toplam tazminat
| CEO maaş yüzdesi | 17.7% |
| CEO görev süresi | 7yrs |
| CEO sahipliği | 0.05% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 6.1yrs |
Son yönetim güncellemeleri
Recent updates
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Tazminat ve Piyasa: Ed's total compensation ($USD3.53M) is about average for companies of similar size in the US market ($USD3.23M).
Tazminat ve Kazançlar: Ed's compensation has been consistent with company performance over the past year.
CEO
Ed Kaye (75 yo)
7yrs
Görev süresi
US$3,533,210
Tazminat
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$3.53m | 0.051% $ 331.8k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.77% $ 5.0m | |
| Chief Medical Officer | 7yrs | US$1.65m | 0.0047% $ 30.5k | |
| Co-Founder & Senior VP of Discovery Research | no data | Veri yok | Veri yok | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Corporate Secretary & General Counsel | 3.8yrs | Veri yok | 0.0049% $ 31.9k | |
| Chief Communications Officer | 3.8yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | 5yrs | Veri yok | Veri yok | |
| Chief Business Officer | less than a year | US$869.86k | 0% $ 0 | |
| Chief Regulatory Officer | 5.8yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | less than a year | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş
Deneyimli Yönetim: STOK's management team is considered experienced (3.8 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$3.53m | 0.051% $ 331.8k | |
| Co-Founder & Independent Director | 10.3yrs | US$198.33k | 0.77% $ 5.0m | |
| Independent Chairman of the Board | 9.3yrs | US$237.33k | 3.56% $ 23.0m | |
| Independent Director | 9.1yrs | US$198.33k | 0.034% $ 221.0k | |
| Independent Director | 1.1yrs | US$394.03k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$209.33k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$211.83k | 0.060% $ 390.1k |
6.1yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: STOK's board of directors are considered experienced (6.1 years average tenure).